8,257 reports of this reaction
7.4% of all DABIGATRAN ETEXILATE reports
#1 most reported adverse reaction
GASTROINTESTINAL HAEMORRHAGE is the #1 most commonly reported adverse reaction for DABIGATRAN ETEXILATE, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.. There are 8,257 FDA adverse event reports linking DABIGATRAN ETEXILATE to GASTROINTESTINAL HAEMORRHAGE. This represents approximately 7.4% of all 111,048 adverse event reports for this drug.
Patients taking DABIGATRAN ETEXILATE who experience gastrointestinal haemorrhage should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GASTROINTESTINAL HAEMORRHAGE is moderately reported among DABIGATRAN ETEXILATE users, representing a notable but not dominant share of adverse events.
In addition to gastrointestinal haemorrhage, the following adverse reactions have been reported for DABIGATRAN ETEXILATE:
The following drugs have also been linked to gastrointestinal haemorrhage in FDA adverse event reports:
GASTROINTESTINAL HAEMORRHAGE has been reported as an adverse event in 8,257 FDA reports for DABIGATRAN ETEXILATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
GASTROINTESTINAL HAEMORRHAGE accounts for approximately 7.4% of all adverse event reports for DABIGATRAN ETEXILATE, making it one of the most commonly reported side effect.
If you experience gastrointestinal haemorrhage while taking DABIGATRAN ETEXILATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.